PT2490688E - Terapêutica de combinação contra o cancro com compostos inibidores de hsp90 - Google Patents
Terapêutica de combinação contra o cancro com compostos inibidores de hsp90 Download PDFInfo
- Publication number
- PT2490688E PT2490688E PT107683575T PT10768357T PT2490688E PT 2490688 E PT2490688 E PT 2490688E PT 107683575 T PT107683575 T PT 107683575T PT 10768357 T PT10768357 T PT 10768357T PT 2490688 E PT2490688 E PT 2490688E
- Authority
- PT
- Portugal
- Prior art keywords
- therapeutics
- inhibitor compounds
- against cancer
- hsp90 inhibitor
- combination against
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27933009P | 2009-10-19 | 2009-10-19 | |
| US33577810P | 2010-01-11 | 2010-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2490688E true PT2490688E (pt) | 2014-12-29 |
Family
ID=43218142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107683575T PT2490688E (pt) | 2009-10-19 | 2010-10-19 | Terapêutica de combinação contra o cancro com compostos inibidores de hsp90 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120245186A1 (OSRAM) |
| EP (1) | EP2490688B1 (OSRAM) |
| JP (2) | JP2013508378A (OSRAM) |
| KR (1) | KR20120093970A (OSRAM) |
| CN (1) | CN102695504A (OSRAM) |
| AU (1) | AU2010308306A1 (OSRAM) |
| BR (1) | BR112012009215A2 (OSRAM) |
| CA (1) | CA2779233A1 (OSRAM) |
| CY (1) | CY1115902T1 (OSRAM) |
| DK (1) | DK2490688T3 (OSRAM) |
| EA (1) | EA022119B1 (OSRAM) |
| ES (1) | ES2526566T3 (OSRAM) |
| HR (1) | HRP20141150T1 (OSRAM) |
| MX (1) | MX2012004577A (OSRAM) |
| NZ (2) | NZ622713A (OSRAM) |
| PH (1) | PH12012500748A1 (OSRAM) |
| PL (1) | PL2490688T3 (OSRAM) |
| PT (1) | PT2490688E (OSRAM) |
| RS (1) | RS53716B1 (OSRAM) |
| SI (1) | SI2490688T1 (OSRAM) |
| WO (1) | WO2011049946A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5178515B2 (ja) | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するピラゾール化合物 |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| EP2026797A2 (en) | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Method for treating non-hodgkin's lymphoma |
| US8053456B2 (en) | 2006-05-25 | 2011-11-08 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| WO2009139916A1 (en) * | 2008-05-16 | 2009-11-19 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate hsp90 activity |
| WO2009148599A1 (en) | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| ES2415234T3 (es) * | 2008-08-08 | 2013-07-24 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad Hsp90 |
| EP2323737A2 (en) | 2008-08-08 | 2011-05-25 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| SG182662A1 (en) | 2010-01-28 | 2012-08-30 | Harvard College | Compositions and methods for enhancing proteasome activity |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| US20130172333A1 (en) * | 2010-05-20 | 2013-07-04 | Synta Pharmaceuticals Corp. | Formulation and dosing of hsp90 inhibitory compounds |
| AU2011255438A1 (en) * | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
| WO2011149824A1 (en) * | 2010-05-24 | 2011-12-01 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| AU2011302344B2 (en) * | 2010-09-13 | 2015-01-15 | Synta Pharmaceuticals Corp. | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients |
| WO2012154967A1 (en) | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| EP2714039A1 (en) * | 2011-05-23 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| WO2012162372A1 (en) * | 2011-05-24 | 2012-11-29 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors |
| EP2714033A1 (en) * | 2011-05-26 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| EP2729144A2 (en) * | 2011-07-07 | 2014-05-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| JP2014534228A (ja) * | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| JP2014532712A (ja) * | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法 |
| AU2012339679A1 (en) * | 2011-11-14 | 2014-06-12 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with BRAF inhibitors |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| WO2017024310A1 (en) | 2015-08-06 | 2017-02-09 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
| CN105237533B (zh) * | 2015-10-26 | 2017-03-22 | 中国药科大学 | 四氢吡啶并[4,3‑d]嘧啶类Hsp90抑制剂及其医药用途 |
| WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP2021098692A (ja) | 2019-12-20 | 2021-07-01 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | 核内受容体に対して活性の化合物 |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| CN101072759B (zh) | 2004-11-18 | 2013-06-19 | Synta医药公司 | 调节hsp90活性的三唑化合物 |
| CA2653217A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| CA2680161A1 (en) * | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
| WO2009002321A1 (en) | 2007-06-27 | 2008-12-31 | Thomson Licensing | Enhancing image quality |
| AU2008287367B2 (en) * | 2007-08-13 | 2012-02-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| EP2729144A2 (en) * | 2011-07-07 | 2014-05-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
-
2010
- 2010-10-19 HR HRP20141150AT patent/HRP20141150T1/hr unknown
- 2010-10-19 KR KR1020127012977A patent/KR20120093970A/ko not_active Ceased
- 2010-10-19 JP JP2012535301A patent/JP2013508378A/ja not_active Ceased
- 2010-10-19 NZ NZ622713A patent/NZ622713A/en not_active IP Right Cessation
- 2010-10-19 PT PT107683575T patent/PT2490688E/pt unknown
- 2010-10-19 ES ES10768357.5T patent/ES2526566T3/es active Active
- 2010-10-19 US US13/501,608 patent/US20120245186A1/en not_active Abandoned
- 2010-10-19 WO PCT/US2010/053199 patent/WO2011049946A1/en not_active Ceased
- 2010-10-19 PH PH1/2012/500748A patent/PH12012500748A1/en unknown
- 2010-10-19 RS RS20140705A patent/RS53716B1/sr unknown
- 2010-10-19 CA CA2779233A patent/CA2779233A1/en not_active Abandoned
- 2010-10-19 NZ NZ599445A patent/NZ599445A/en not_active IP Right Cessation
- 2010-10-19 MX MX2012004577A patent/MX2012004577A/es active IP Right Grant
- 2010-10-19 DK DK10768357.5T patent/DK2490688T3/en active
- 2010-10-19 CN CN201080056689XA patent/CN102695504A/zh active Pending
- 2010-10-19 AU AU2010308306A patent/AU2010308306A1/en not_active Abandoned
- 2010-10-19 BR BR112012009215A patent/BR112012009215A2/pt not_active IP Right Cessation
- 2010-10-19 SI SI201030832T patent/SI2490688T1/sl unknown
- 2010-10-19 EP EP10768357.5A patent/EP2490688B1/en active Active
- 2010-10-19 PL PL10768357T patent/PL2490688T3/pl unknown
- 2010-10-19 EA EA201270570A patent/EA022119B1/ru not_active IP Right Cessation
-
2014
- 2014-12-31 CY CY20141101097T patent/CY1115902T1/el unknown
-
2015
- 2015-10-08 JP JP2015199844A patent/JP2016041715A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS53716B1 (sr) | 2015-04-30 |
| AU2010308306A1 (en) | 2012-05-10 |
| PH12012500748A1 (en) | 2012-10-29 |
| DK2490688T3 (en) | 2014-12-08 |
| KR20120093970A (ko) | 2012-08-23 |
| NZ599445A (en) | 2014-04-30 |
| NZ622713A (en) | 2015-07-31 |
| US20120245186A1 (en) | 2012-09-27 |
| CN102695504A (zh) | 2012-09-26 |
| CA2779233A1 (en) | 2011-04-28 |
| EP2490688A1 (en) | 2012-08-29 |
| MX2012004577A (es) | 2012-06-13 |
| HK1175112A1 (en) | 2013-06-28 |
| SI2490688T1 (sl) | 2015-01-30 |
| PL2490688T3 (pl) | 2015-03-31 |
| ES2526566T3 (es) | 2015-01-13 |
| BR112012009215A2 (pt) | 2019-09-24 |
| JP2016041715A (ja) | 2016-03-31 |
| WO2011049946A1 (en) | 2011-04-28 |
| HRP20141150T1 (hr) | 2015-01-30 |
| EA022119B1 (ru) | 2015-11-30 |
| CY1115902T1 (el) | 2017-01-25 |
| EA201270570A1 (ru) | 2012-09-28 |
| JP2013508378A (ja) | 2013-03-07 |
| EP2490688B1 (en) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2490688E (pt) | Terapêutica de combinação contra o cancro com compostos inibidores de hsp90 | |
| DOP2012000114A (es) | Inhibidor bromodominio de benzodiazepina | |
| EP2272817A4 (en) | PAI-1 INHIBITORS | |
| SG10201601846VA (en) | Rnai inhibition of alpha-enac expression | |
| EP2350110A4 (en) | NEW STEVIOLGLYKOSIDE | |
| SMT201600104B (it) | Inibitore di bromodominio benzodiazepinico | |
| BRPI1016032A2 (pt) | conjunto dual de tensionador. | |
| ZA201107140B (en) | Inhibition of biofilm organisms | |
| ZA201300004B (en) | Cyrstalline form of benzylbenzene sglt2 inhibitor | |
| IL208136A0 (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases | |
| GB0820970D0 (en) | Suppression of cancer | |
| IL205831A0 (en) | Kinesin inhibitors as cancer therapeutics | |
| LT2506840T (lt) | Hipoksija sukeliančio faktoriaus inhibitorių naudojimas | |
| GB0820309D0 (en) | Detection of cancer | |
| FI20096405A0 (fi) | Teräsrakenteinen ovi | |
| EP2408950A4 (en) | ELECTRO-RECOVERY OF METALS | |
| CU23884B1 (es) | Derivados de dibenzotiazepina | |
| EP2242714A4 (en) | Protective insert | |
| FR2953411B1 (fr) | Combinaison synergique de composes analgesiques | |
| PL2237782T3 (pl) | Zastosowanie tetrahydropirymidyn | |
| SMT201500123B (it) | Dosaggio unitario di apadenoson | |
| IT1396939B1 (it) | Composizione idrocarburica utile come carburante o combustibile | |
| FR2937553B1 (fr) | Combinaison synergique de composes analgesiques | |
| FR2944196B1 (fr) | Montant de rayonnage renforce | |
| GB0808286D0 (en) | Inhibitors of HSP90 |